跳至主要内容
临床试验/TCTR20240510001
TCTR20240510001尚未招募3 期

Effects of a combination of ultra-low dose estriol and Lactobacillus vaginal tablet (Gynoflor) in reducing post radiation vaginitis in cervical cancer patients: A randomized controlled trial

Songklanagarind Hospital0 个研究点目标入组 34 人开始时间: 2024年5月10日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 Years 至 75 Years(—)
性别
Female

入选标准

  • 1. Stage I to Stage III (according to FIGO staging 2018) cervical cancer patients who completed radiotherapy treatment within 3-6 months
  • 2. Thai ethnicity
  • 3. Experiencing vaginal toxicities symptoms which affect quality of life

排除标准

  • 1. Current severe vaginal infection
  • 2. Current contact allergy in vulvovaginal area
  • 3. Genital structure abnormality
  • 4. Use of other vaginal route drugs within 2 weeks
  • 5. Use of other hormonal therapy within 3 months
  • 6. Hypersensitivity to Gynoflor composition both active and inactive ingredients
  • 7. Existing or suspected estrogen-dependent tumors in the breast, uterus, or ovaries
  • 8. Vaginal bleeding of unknown origin
  • 9. Recurrent or progressive disease
  • 10. Patients with contraindication for using estrogen i.e. DVT VTE SLE with positive APS antibodies or other vascular diseases

研究者

发起方
Songklanagarind Hospital

相似试验